Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Glioblastoma Multiforme Treatment Market , by Region, 2019-2027 (USD Billion)
1.2.2. Glioblastoma Multiforme Treatment Market , by Treatment , 2019-2027 (USD Billion)
1.2.3. Glioblastoma Multiforme Treatment Market , by Drug class, 2019-2027 (USD Billion)
1.2.4. Glioblastoma Multiforme Treatment Market , by End use, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Glioblastoma Multiforme Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Glioblastoma Multiforme Treatment Market Dynamics
3.1. Glioblastoma Multiforme Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of glioblastoma multiforme
3.1.1.2. Increase in incidences of brain tumours
3.1.2. Market Restraint
3.1.2.1. Lack of effective therapies for glioblastoma multiforme
3.1.2.2. High cost associated with the development of drug and stringent regulations
3.1.3. Market Opportunities
3.1.3.1. Growth in rate of approval for novel therapy and combination therapy
Chapter 4. Global Glioblastoma Multiforme Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Glioblastoma Multiforme Treatment Market , by Treatment
5.1. Market Snapshot
5.2. Global Glioblastoma Multiforme Treatment Market by Treatment , Performance - Potential Analysis
5.3. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Treatment 2018-2027 (USD Billion)
5.4. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
5.4.1. Surgery
5.4.2. Radiation Therapy
5.4.3. Chemotherapy
5.4.4. Targeted Therapy
5.4.5. Tumor Treating Fields Therapy
5.4.6. Immunotherapy
Chapter 6. Global Glioblastoma Multiforme Treatment Market , by Drug Class
a. Market Snapshot
6.1. Global Glioblastoma Multiforme Treatment Market by Drug Class, Performance - Potential Analysis
6.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Drug class2018-2027 (USD Billion)
6.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
6.3.1. Temozolomide
6.3.2. Bevacizumab
6.3.3. Lomustine
6.3.4. Carmustine Wafers
6.3.5. Others
Chapter 7. Global Glioblastoma Multiforme Treatment Market , by End use
b. Market Snapshot
7.1. Global Glioblastoma Multiforme Treatment Market by End use, Performance - Potential Analysis
7.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by End use 2018-2027 (USD Billion)
7.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Ambulatory Surgical Centers
Chapter 8. Global Glioblastoma Multiforme Treatment Market , Regional Analysis
8.1. Glioblastoma Multiforme Treatment Market , Regional Market Snapshot
8.2. North America Glioblastoma Multiforme Treatment Market
8.2.1. U.S. Glioblastoma Multiforme Treatment Market
8.2.1.1. Treatment breakdown estimates & forecasts, 2018-2027
8.2.1.2. Drug class breakdown estimates & forecasts, 2018-2027
8.2.1.3. End use breakdown estimates & forecasts, 2018-2027
8.2.2. Canada Glioblastoma Multiforme Treatment Market
8.3. Europe Glioblastoma Multiforme Treatment Market Snapshot
8.3.1. U.K. Glioblastoma Multiforme Treatment Market
8.3.2. Germany Glioblastoma Multiforme Treatment Market
8.3.3. France Glioblastoma Multiforme Treatment Market
8.3.4. Spain Glioblastoma Multiforme Treatment Market
8.3.5. Italy Glioblastoma Multiforme Treatment Market
8.3.6. Rest of Europe Glioblastoma Multiforme Treatment Market
8.4. Asia-Pacific Glioblastoma Multiforme Treatment Market Snapshot
8.4.1. China Glioblastoma Multiforme Treatment Market
8.4.2. India Glioblastoma Multiforme Treatment Market
8.4.3. Japan Glioblastoma Multiforme Treatment Market
8.4.4. Australia Glioblastoma Multiforme Treatment Market
8.4.5. South Korea Glioblastoma Multiforme Treatment Market
8.4.6. Rest of Asia Pacific Glioblastoma Multiforme Treatment Market
8.5. Latin America Glioblastoma Multiforme Treatment Market Snapshot
8.5.1. Brazil Glioblastoma Multiforme Treatment Market
8.5.2. Mexico Glioblastoma Multiforme Treatment Market
8.6. Rest of The World Glioblastoma Multiforme Treatment Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Merck & Co., Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
9.2.3. Teva Pharmaceutical Industries Ltd.
9.2.4. Sun Pharmaceutical Industries Ltd.
9.2.5. Hoffmann-La Roche Ltd.
9.2.6. Pfizer, Inc.
9.2.7. Amgen, Inc.
9.2.8. Arbor Pharmaceuticals, LLC
9.2.9. Amneal Pharmaceuticals
9.2.10. Karyopharm Therapeutics, Inc.

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption